Skip to content
Screener

CapEx at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$52K-61.5%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$3.18M+337%
Alumis Inc. logo
Alumis Inc.ALMS
$164K+343%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$18K+800%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$473K-31.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$240.2M+9.7%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNotesSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Change in operating lease liabilities and right of use assets6(0.1)0.3
Net cash flow used in operating activities(101.7)(53.6)
Cash flows used in investing activities :
Change in property, plant, and equipment(0.8)
Change in Other non-current assets5(0.1)(0.4)
Net cash flows used in investing activities(0.9)(0.4)
Cash flows provided by financing activities :
Treasury shares0.1

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's capex?
DBV Technologies (DBVT) reported capex of $400K in Q2 2026.
What is the long-term trend for DBV Technologies's capex?
Over 3 years (2022 to 2025), DBV Technologies's capex has grown at a -11.0% compound annual growth rate (CAGR), from $754K to $532K.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about DBV Technologies's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude